Abstract
Gene therapy is a hopeful strategy for the treatment of retinal disorders with no effective treatment. Gene replacement therapy is the most widely used strategy to modulate the gene expression in clinical research of inherited or acquired ocular diseases. Viral vectors are at the forefront of translational gene therapy mainly due to their high efficacy; nevertheless, concerns regarding safety have fostered the progress of nonviral therapy. Nonviral systems are non-immunogenic and avoid the risk of insertional mutagenesis. Moreover, they can be easily produced at large scale and have the potential to deliver larger genetic payloads. However, vector engineering to attain tissue-selective targeting and/or regulate the extent of gene expression is a challenging issue of nonviral gene therapy. Subretinal or intravitreal injections are the best option for the success of gene delivery to the posterior segment of the eye, regardless of the type of vector used. Preclinical studies with nonviral vectors have shown encouraging results for the treatment of macular degeneration and some inherited retinal disorders such as X-linked retinoschisis, Stargardt disease, retinitis pigmentosa, and Leber congenital amaurosis. These recent advances point to nonviral gene therapy as a feasible therapeutic tool for retinal disorders.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Abul-Hassan K, et al. Optimization of non-viral gene transfer to human primary retinal pigment epithelial cells. Curr Eye Res. 2000;20:361–6.
Aied A, et al. Polymer gene delivery: overcoming the obstacles. Drug Discov Today. 2013;18:1090–8.
Al-Saikhan FI. The gene therapy revolution in ophthalmology. Saudi J Ophthalmol. 2013;27:107–11.
Allikmets R, et al. A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Nat Genet. 1997;15:236–46.
Apaolaza PS, et al. A novel gene therapy vector based on hyaluronic acid and solid lipid nanoparticles for ocular diseases. Int J Pharm. 2014;465:413–26.
Apaolaza PS, et al. Solid lipid nanoparticle-based vectors intended for the treatment of X-linked juvenile retinoschisis by gene therapy: in vivo approaches in Rs1h-deficient mouse model. J Control Release. 2015;217:273–83.
Apaolaza PS, et al. Structural recovery of the retina in a retinoschisin-deficient mouse after gene replacement therapy by solid lipid nanoparticles. Biomaterials. 2016;90:40–9.
Arnedo A, et al. Albumin nanoparticles improved the stability, nuclear accumulation and anticytomegaloviral activity of a phosphodiester oligonucleotide. J Control Release. 2004;94:217–27.
Bainbridge JW, et al. Effect of gene therapy on visual function in Leber’s congenital amaurosis. N Engl J Med. 2008;358:2231–9.
Banin E, et al. Molecular anthropology meets genetic medicine to treat blindness in the North African Jewish population: human gene therapy initiated in Israel. Hum Gene Ther. 2010;21:749–1757.
Battaglia L, et al. Application of lipid nanoparticles to ocular drug delivery. Expert Opin Drug Deliv. 2016;13:1743–57.
Bejjani RA, et al. Nanoparticles for gene delivery to retinal pigment epithelial cells. Mol Vis. 2005;11:124–32.
Berger W, et al. The molecular basis of human retinal and vitreoretinal diseases. Prog Retin Eye Res. 2010;29:335–75.
Binley K, et al. Transduction of photoreceptors with equine infectious anemia virus lentiviral vectors: safety and biodistribution of StarGen for Stargardt disease. Invest Ophthalmol Vis Sci. 2013;54:4061–71.
Bitoque DB, et al. Efficiency of RAFT-synthesized PDMAEMA in gene transfer to the retina. J Tissue Eng Regen Med. 2017;11:265–75.
Bloquel C, et al. Potential ocular therapeutic avenues. Adv Drug Deliv Rev. 2006;58:1224–42.
Breunig M, et al. Gene delivery with low molecular weight linear polyethylenimines. J Gene Med. 2005;7:1287–98.
Bush RA, et al. Convergence of human genetics and animal studies: gene therapy for X-linked retinoschisis. Cold Spring Harb Perspect Med. 2015;5:a017368.
Bush RA, et al. Preclinical dose-escalation study of intravitreal AAV-RS1 gene therapy in a mouse model of X-linked Retinoschisis: dose-dependent expression and improved retinal structure and function. Hum Gene Ther. 2016;27:376–89.
Cai X, et al. Nanoparticle applications in ocular gene therapy. Vis Res. 2008;48:319–24.
Cai X, et al. Gene delivery to mitotic and postmitotic photoreceptors via compacted DNA nanoparticles results in improved phenotype in a mouse model of retinitis pigmentosa. FASEB J. 2010;24:1178–91.
Campochiaro PA, et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther. 2006;17:167–76.
Carrasquillo KG, et al. Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres. Invest Ophthalmol Vis Sci. 2003;44:290–9.
Chalberg TW, et al. phiC31 integrase confers genomic integration and long-term transgene expression in rat retina. Invest Ophthalmol Vis Sci. 2005;46:2140–6.
Chen CW, et al. Efficient downregulation of VEGF in retinal pigment epithelial cells by integrin ligand-labeled liposome-mediated siRNA delivery. Int J Nanomedicine. 2013;8:2613–27.
Cheung LK, Eaton A. Age-related macular degeneration. Pharmacotherapy. 2013;33:838–55.
Cideciyan AV, et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci U S A. 2008;105:15112–7.
Clinical-Trials.gov. Phase I/IIa study of SAR422459 in patients with Stargardt’s macular degeneration. StarGen, Clinical-Trialsgov number, NCT01367444. https://clinicaltrials.gov/ct2/show/NCT01367444. Last query: 26 June 2017.
Cohen RN, et al. Quantification of plasmid DNA copies in the nucleus after lipoplex and polyplex transfection. J Control Release. 2009;135:166–74.
Conley SM, Naash MI. Nanoparticles for retinal gene therapy. Prog Retin Eye Res. 2010;29:376–97.
Connell G, et al. Photoreceptor peripherin is the normal product of the gene responsible for retinal degenera-tion in the rds mouse. Proc Natl Acad Sci U S A. 1991;88:723–6.
Cox DB, et al. Therapeutic genome editing: prospects and challenges. Nat Med. 2015;21:121–31.
Cremers FP, et al. Autosomal recessive retinitis pigmentosa and cone-rod dystrophy caused by splice site mutations in Stargardts disease ABCR. Hum Mol Gen. 1998;7:355–62.
D’Cruz PM, et al. Mutation of the receptor tyrosine kinase gene Mertk in the retinal dystrophic RCS rat. Hum Mol Genet. 2000;9:645–51.
de la Fuente M, et al. Novel hyaluronic acid-chitosan nanoparticles for ocular gene therapy. Invest Ophthalmol Vis Sci. 2008;49:2016–24.
del Pozo-Rodríguez A, et al. Solid lipid nanoparticles for retinal gene therapy: transfection and intracellular trafficking in RPE cells. Int J Pharm. 2008;360:177–83.
del Pozo-Rodríguez A, et al. A proline-rich peptide improves cell transfection of solid lipid nanoparticle-based non-viral vectors. J Control Release. 2009;133:52–9.
del Pozo-Rodríguez A, et al. Lipid nanoparticles as drug/gene delivery systems to the retina. J Ocul Pharmacol Ther. 2013;29:173–88.
del Pozo-Rodríguez A, et al. Applications of lipid nanoparticles in gene therapy. Eur J Pharm Biopharm. 2016;109:184–93.
Delgado D, et al. Understanding the mechanism of protamine in solid lipid nanoparticle-based lipofection: the importance of the entry pathway. Eur J Pharm Biopharm. 2011;79:495–502.
Delgado D, et al. Dextran-protamine-solid lipid nanoparticles as a non-viral vector for gene therapy: in vitro characterization and in vivo transfection after intravenous administration to mice. Int J Pharm. 2012a;425:35–43.
Delgado D, et al. Dextran and protamine-based solid lipid nanoparticles as potential vectors for the treatment of X-linked juvenile retinoschisis. Hum Gene Ther. 2012b;23:345–55.
Delgado D, et al. New gene delivery system based on oligochitosan and solid lipid nanoparticles: ‘in vitro’ and ‘in vivo’ evaluation. Eur J Pharm Sci. 2013;50:484–91.
European Medicines Agency. Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products. Draft. EMA/CAT/80183/2014, 2015.
Feng L, et al. Ocular delivery of pRNA nanoparticles: distribution and clearance after subconjunctival injection. Pharm Res. 2014;31:1046–58.
Feret A, et al. Macular degeneration: types, causes, and possible interventions. Geriatr Nurs. 2007;28:387–92.
Foged C. siRNA delivery with lipid-based systems: promises and pitfalls. Curr Top Med Chem. 2012;12:97–107.
Fritsche LG, et al. Seven new loci associated with age-related macular degeneration. Nat Genet. 2013;45:433–9.
Gan L, et al. Hyaluronan-modified core-shell liponanoparticles targeting CD44-positive retinal pigment epithelium cells via intravitreal injection. Biomaterials. 2013;34:5978–87.
Gene Therapy Clin Trials Worldwide. Provided by the Journal of GeneMedicine. Jon Wiley and Sons Ltd., 2017. http://www.abedia.com/wiley/indications.php. Updated Apr 2017; last query: 26 June 2017.
Ghazi NG, et al. Treatment of retinitis pigmentosa due to MERTK mutations by ocular sub-retinal injection of adeno-associated virus gene vector: results of a phase I trial. Hum Genet. 2016;135:327–43.
Gomes dos Santos AL, et al. Oligonucleotide-polyethylenimine complexes targeting retinal cells: structural analysis and application to anti-TGFbeta-2 therapy. Pharm Res. 2006;23:770–81.
Hafler BP. Clinical progress in inherited retinal degenerations: gene therapy clinical trials and advances in genetic sequencing. Retina. 2017;37:417–23.
Hamel C. Retinitis pigmentosa. Orphanet J Rare Dis. 2006;1:40.
Han Z, et al. DNA nanoparticle-mediated ABCA4 delivery rescues Stargardt dystrophy in mice. J Clin Invest. 2012;122:3221–6.
Janssen A, et al. Effect of late-stage therapy on disease progression in AAV-mediated rescue of photoreceptor cells in the retinoschisin deficient mouse. Mol Ther. 2008;16:1010–7.
Johnen S, et al. Sleeping Beauty transposon-mediated transfection of retinal and iris pigment epithelial cells. Invest Ophthalmol Vis Sci. 2012;53:4787–96.
Hudecek M, et al. Going non-viral: the sleeping beauty transposon system breaks on through to the clinical side. Crit Rev Biochem Mol Biol. 2017;52:355–80.
Horbinski C, et al. Polyethyleneimine-mediated transfection of cultured postmitotic neurons from rat sympathetic ganglia and adult human retina. BMC Neurosci. 2001;2:2.
Kaur IP, Kakkar S. Nanotherapy for posterior eye diseases. J Control Release. 2014;193:100–12.
Kay MA, et al. A robust system for production of minicircle DNA vectors. Nature Biotech. 2010;28:1287–9.
Koirala A, et al. A review of therapeutic prospects of non-viral gene therapy in the retinal pigment epithelium. Biomaterials. 2013a;34:7158–67.
Koirala A, et al. S/MAR-containing DNA nanoparticles promote persistent RPE gene expression and improvement in RPE65-associated LCA. Hum Mol Genet. 2013b;22:1632–42.
Koirala A, et al. Episomal maintenance of S/MAR-containing non-viral vectors for RPE-based diseases. Adv Exp Med Biol. 2014;801:703–9.
Kurosaki T, et al. Ocular gene delivery systems using ternary complexes of plasmid DNA, polyethylenimine, and anionic polymers. Biol Pharm Bull. 2013;36:96–101.
Ladas ID, et al. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. Retina. 2009;29:313–8.
Lhériteau E, et al. Successful gene therapy in the RPGRIP1-deficient dog: a large model of cone-rod dystrophy. Mol Ther. 2014;22:265–77.
Maguire AM, et al. Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med. 2008;358:2240–8.
Mannermaa E, et al. Long-lasting secretion of transgene product from differentiated and filter-grown retinal pigment epithelial cells after nonviral gene transfer. Curr Eye Res. 2005;30:345–53.
Männistö M, et al. Structure-activity relationships of poly(L-lysines): effects of pegylation and molecular shape on physicochemical and biological properties in gene delivery. J Control Release. 2002;83:169–82.
Marano RJ, et al. Inhibition of in vitro VEGF expression and choroidal neovascularization by synthetic dendrimer peptide mediated delivery of a sense oligonucleotide. Exp Eye Res. 2004;79:525–35.
Martinez-Mir A, et al. Retinitis pigmentosa caused by a homozygous mutation in the Stargardt disease ABCR. Nat Genet. 1998;18:11–2.
Mashal M, et al. Retinal gene delivery enhancement by lycopene incorporation into cationic niosomes based on DOTMA and polysorbate 60. J Control Release. 2017;254:55–64.
Masuda I, et al. Gene transfer with liposomes to the intraocular tissues by different routes of administration. Invest Ophthalmol Vis Sci. 1996;37:1914–20.
Michalakis S, et al. Gene therapy restores vision and delays degeneration in the CNGB1(−/−) mouse model of retinitis pigmentosa. Adv Exp Med Biol. 2014;801:733–9.
Millington-Ward S, et al. Strategems in vitro for gene therapies directed to dominant mutations. Hum Mol Genet. 1997;6:1415–26.
Mohan RR, et al. Corneal gene therapy: basic science and translational perspective. Ocul Surf. 2013;11:150–64.
Molday RS, Zhang K. Defective lipid transport and biosynthesis in recessive and dominant Stargardt macular degeneration. Prog Lipid Res. 2010;49:476–92.
Naik R, et al. Gene delivery to the retina: focus on non-viral approaches. Drug Discov Today. 2009;14:306–15.
Ojeda E, et al. The in fluence of the polar head-group of synthetic cationic lipids on the transfection efficiency mediated by niosomes in rat retina and brain. Biomaterials. 2016;77:267–79.
Oliveira C, et al. Recent advances in characterization of nonviral vectors for delivery of nucleic acids: impact on their biological performance. Expert Opin Drug Deliv. 2015;12:27–39.
Oliveira AV, et al. Non-viral strategies for ocular gene delivery. Mater Sci Eng C Mater Biol Appl. 2017;77:1275–89.
Ou J, et al. Synaptic pathology and therapeutic repair in adult retinoschisis mouse by AAV-RS1 transfer. J Clin Invest. 2015;125:2891–903.
Park TK, et al. Intravitreal delivery of AAV8 retinoschisin results in cell type-specific gene expression and retinal rescue in the Rs1-KO mouse. Gene Ther. 2009;16:916–26.
Peeters L, et al. Vitreous: a barrier to nonviral ocular gene therapy. Invest Ophthalmol Vis Sci. 2005;46:3553–61.
Pensado A, et al. Span poly-L-arginine nanoparticles are efficient non-viral vectors for PRPF31 gene delivery: an approach of gene therapy to treat retinitis pigmentosa. Nanomedicine. 2016;12:2251–60.
Petrs-Silva H, Linden R. Advances in gene therapy technologies to treat retinitis pigmentosa. Clin Ophthalmol. 2014;8:127–36.
Rajala A, et al. Nanoparticle-assisted targeted delivery of eye-specific genes to eyes significantly improves the vision of blind mice in vivo. Nano Lett. 2014;14:5257–63.
Rodríguez-Gascón A, et al. Vaginal gene therapy. Adv Drug Deliv Rev. 2015;92:71–83.
Ruiz de Garibay AP, et al. Role of endocytic uptake in transfection efficiency of solid lipid nanoparticles-based nonviral vectors. J Gene Med. 2013;15:427–40.
Sikkink SK, et al. X-linked retinoschisis: an update. J Med Genet. 2007;44:225–32.
Sochor MA, et al. An autogenously regulated expression system for gene therapeutic ocular applications. Sci Report. 2015;5:17105.
Solinís MA, et al. Treatment of ocular disorders by gene therapy. Eur J Pharm Biopharm. 2015;95:331–42.
Tantri A, et al. X-linked retinoschisis: a clinical and molecular genetic review. Surv Ophthalmol. 2004;49:214–30.
Thumann G. Prospectives for gene therapy of retinal degenerations. Curr Genomics. 2012;13:350–62.
Trapani I, et al. Vector platforms for gene therapy of inherited retinopathies. Prog Retin Eye Res. 2014;43:108–28.
Touchard E, et al. Suprachoroidal electrotransfer: a nonviral gene delivery method to transfect the choroid and the retina without detaching the retina. Mol Ther. 2012;20:1559–70.
Travis GH, et al. The retinal degeneration slow (rds) gene product is a photoreceptor discmembrane-associated glycoprotein. Neuron. 1991;6:61–70.
Van Lookeren Campagne M, et al. Mechanisms of age-related macular degeneration and therapeutic opportunities. J Pathol. 2014;232:151–64.
Wang Y, et al. Cell-specific promoters enable lipid-based nanoparticles to deliver genes to specific cells of the retina in vivo. Theranostics. 2016;6:1514–27.
Wasungu L, Hoekstra D. Cationic lipids, lipoplexes and intracellular delivery of genes. J Control Release. 2006;116:255–64.
Weber BH, et al. Inactivation of the murine X-linked juvenile retinoschisis gene, Rs1h, suggests a role of retinoschisin in retinal cell layer organization and synaptic structure. Proc Natl Acad Sci U S A. 2002;99:6222–7.
Yamada Y, et al. Hyaluronic acid controls the uptake pathway and intracellular trafficking of an octaarginine-modified gene vector in CD44 positive- and CD44 negative-cells. Biomaterials. 2015;52:189–98.
Yanik M, et al. In vivo genome editing as a potential treatment strategy for inherited retinal dystrophies. Prog Retin Eye Res. 2017;56:1–18.
Yin H, et al. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014;15:541–55.
Zhang Y, et al. Design and biophysical characterization of bioresponsive degradable poly(dimethylaminoethyl methacrylate) based polymers for in vitro DNA transfection. Biomacromolecules. 2012;13:313–22.
Zhu C, et al. Widespread expression of an exogenous gene in the eye after intravenous administration. Invest Ophthalmol Vis Sci. 2002;43:3075–80.
Zulliger R, et al. Non-viral therapeutic approaches to ocular diseases: an overview and future directions. J Control Release. 2015;219:471–87.
Acknowledgments
This work was supported by the University of the Basque Country UPV/EHU (PPG17/65 and GIU17/032). J Torrecilla thanks UPV/EHU for her research grant.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
del Pozo-Rodríguez, A., Torrecilla, J., Rodríguez-Gascón, A., Solinís, M.Á. (2018). Nonviral Delivery Systems for Gene Therapy for Retina and Posterior Segment Disease. In: Patel, J., Sutariya, V., Kanwar, J., Pathak, Y. (eds) Drug Delivery for the Retina and Posterior Segment Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-95807-1_8
Download citation
DOI: https://doi.org/10.1007/978-3-319-95807-1_8
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-95806-4
Online ISBN: 978-3-319-95807-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)